Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dyne Therapeutics Inc (NQ: DYN ) 42.86 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Dyne Therapeutics Inc < Previous 1 2 Next > Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease June 24, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress June 13, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at Jefferies Global Healthcare Conference May 30, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares May 28, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock May 21, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Proposed Public Offering of Common Stock May 20, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints May 20, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET May 19, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 02, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer March 27, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium March 27, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces CEO Transition March 25, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days March 13, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights March 05, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference February 14, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at February Investor Conferences February 01, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares January 11, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference January 05, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock January 04, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Inc. (NASDAQ: DYN) Leading the Way in Thursday Trading Based on Percentage Gain January 04, 2024 Via Investor Brand Network Dyne Therapeutics Announces Proposed Public Offering of Common Stock January 03, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases January 03, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials January 02, 2024 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at November Investor Conferences November 07, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones October 30, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at October Investor Conferences September 28, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 September 20, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference September 05, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights August 03, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire Dyne Therapeutics to Present at Jefferies Healthcare Conference June 01, 2023 From Dyne Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.